CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FierceBiotech
Original article

{"a":[{"_":"China’s Henlius carves out $440M T-cell engager deal with Amberstone","$":{"href":"/biotech/chinas-henlius-carves-out-440m-t-cell-engager-deal-amberstone","hreflang":"en"}}]}

PartnershipPositive
AI Analysis

Summary

Henlius Biotech, a Fosun Pharma subsidiary, entered a $440 million biobucks deal with Amberstone Biosciences to develop T-cell engagers.

Importance:6/10
Sentiment:
0.50
partnershipT-cell engagercollaborationbiobucks deal
Related Companies

Read the original article

Published by FierceBiotech on September 24, 2026 10:03 AM

Read Original